Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

2.45
-0.2800-10.26%
Post-market: 2.520.0697+2.84%19:49 EDT
Volume:591.52K
Turnover:1.51M
Market Cap:36.80M
PE:-0.47
High:2.84
Open:2.75
Low:2.45
Close:2.73
52wk High:26.05
52wk Low:2.27
Shares:15.02M
Float Shares:9.14M
Volume Ratio:2.48
T/O Rate:6.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2498
EPS(LYR):-4.8865
ROE:-101.34%
ROA:-56.50%
PB:0.87
PE(LYR):-0.50

Loading ...

Jasper Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
Mar 20

Jasper Therapeutics Signs New Sales Agreement with Jefferies

TIPRANKS
·
Mar 20

BRIEF-Jasper Therapeutics terminates Cantor sales agreement

Reuters
·
Mar 20

Jasper Therapeutics files $300M mixed securities shelf

TIPRANKS
·
Mar 20

Jasper Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 12

Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics

TIPRANKS
·
Mar 12

Jasper Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 03

Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

TIPRANKS
·
Mar 03

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

TIPRANKS
·
Mar 03

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

TIPRANKS
·
Mar 02

RBC Capital Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)

TIPRANKS
·
Mar 02

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire
·
Mar 02

Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab’s Phase 2b Program

TIPRANKS
·
Mar 01

Jasper Therapeutics Inc expected to post a loss of $1.26 a share - Earnings Preview

Reuters
·
Feb 28

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

GlobeNewswire
·
Feb 28

Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating

TIPRANKS
·
Feb 28

Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab

TIPRANKS
·
Feb 28

Jasper Therapeutics Q4 EPS $(1.62) Misses $(1.23) Estimate

Benzinga
·
Feb 27

Press Release: Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
Feb 27

Jasper Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire
·
Feb 26